Sign in
BSX-BOSTON SCIENTIFIC CORP
Boston Scientific Advances AFib Treatment with CE Mark Approval for Farapulse System and Sees Market Opportunities Amid Competitors' Challenges
Member Only Article
Wednesday
19 February, 2025
Boston Scientific is reshaping the AFib treatment landscape with its Farapulse system, achieving remarkable sales and positioning itself as a leader in the pulsed field ablation market. As competitors face hurdles, can Boston Scientific maintain its momentum and capitalize on this growing opportunity?
Article Impact Score
0
50
100
Underperform
Bearish
Neutral
Bullish
Outperform
0
Key Takeaways
- Loading...
Most Read
Join Foliko Premium!
Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.
Go Premium - 7 Day Free Trial